Company Encyclopedia
View More
name
Longshenrongfa Pharmaceutical Industry
300534.SZ
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells Chinese patent medicines, health food, and APIs in China and internationally. The company offers Xuanfei Zhicough mixture, Yuanhu Zhitong dropping pills, Qiwei Wenyang capsules, Maxing cough capsule, and Astragalus Angelica capsules. Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD was founded in 2002 and is based in Lanzhou, China.
3.159 T
300534.SZMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking163/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE4.17%C
    • Profit Margin3.04%C
    • Gross Margin66.46%A
  • Growth ScoreD
    • Revenue YoY-12.01%E
    • Net Profit YoY-30.11%D
    • Total Assets YoY-3.57%D
    • Net Assets YoY5.09%B
  • Cash ScoreC
    • Cash Flow Margin3286.30%A
    • OCF YoY-12.01%E
  • Operating ScoreB
    • Turnover0.68B
  • Debt ScoreC
    • Gearing Ratio42.84%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Longshenrongfa Pharmaceutical Industry released its performance for the first three quarters, with a net profit attributable to the parent company of 27.0294 million yuan, an increase of 8.11%

    Longshenrongfa Pharmaceutical Industry released its Q3 2025 report, with operating revenue for the first three quarters at 647 million yuan, a year-on-year decrease of 16.12%. The net profit attributable to the parent company was 27.0294 million yuan, a year-on-year increase of 8.11%. The net profit after deducting non-recurring gains and losses was 28.7134 million yuan, a year-on-year increase of 31.14%. The basic earnings per share were 0.0891 yuan

    Zhitong·
    SZ
    300534
    -0.67%
    Zhitong·
    SZ
    300534
    -0.67%

    Longshenrongfa Pharmaceutical Industry: Net profit loss of 926,700 yuan in the third quarter

    Longshenrongfa Pharmaceutical Industry announced that its revenue for the third quarter was 151 million yuan, a year-on-year decrease of 34.63%; the net profit loss was 926,700 yuan. Revenue for the first three quarters was 647 million yuan, a year-on-year decrease of 16.12%; the net profit was 27.0294 million yuan, a year-on-year increase of 8.11%

    Zhitong·
    SZ
    300534
    -0.67%
    Zhitong·
    SZ
    300534
    -0.67%

    Longshenrongfa Pharmaceutical Industry: Zhao Zhengcai resigns as Chief Financial Officer, Xiao Rong takes over

    On September 26th, Longshenrongfa Pharmaceutical Industry announced that Chief Financial Officer Zhao Zhengcai resigned due to work adjustments. After resigning, he will serve at the controlling shareholder and will no longer hold any administrative positions in the company or its subsidiaries. The company's board of directors approved the appointment of Xiao Rong as the new Chief Financial Officer on the same day, with a term until the end of the fifth board of directors

    Zhitong·
    SZ
    300534
    -0.67%
    Zhitong·
    SZ
    300534
    -0.67%

    Longshenrongfa Pharmaceutical Industry: The holding subsidiary has obtained the renewed "Drug Manufacturing License"

    Longshenrongfa Pharmaceutical Industry announced that its holding subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has completed the renewal procedures for the "Drug Production License" due to the application for the reduction of entrusted production related matters. On September 25, 2025, it received the renewed "Drug Production License" approved by the Gansu Provincial Drug Administration. The change in this "Drug Production License" is mainly due to Puan Pharmaceutical's application for the reduction of the entrusted production of the Xuanfei Zhike Decoction, and the change procedures have been completed in accordance with the law, which will not have a significant impact on production and operations

    Zhitong·
    SZ
    300534
    -0.67%
    Zhitong·
    SZ
    300534
    -0.67%

    Longshenrongfa Pharmaceutical Industry: Tongmai Oral Liquid Approved for Market Sale

    Longshenrongfa Pharmaceutical Industry's holding subsidiary Gansu Puan Pharmaceutical has received approval from the Gansu Provincial Drug Administration. Tongmai Oral Solution has passed the on-site inspection and technical review for drug production, meeting the conditions for market sales. This medication is primarily used for the treatment of ischemic cardiovascular and cerebrovascular diseases, arteriosclerosis, and other related conditions

    Zhitong·
    SZ
    300534
    -0.67%
    Zhitong·
    SZ
    300534
    -0.67%
    © 2025 Longbridge｜Disclaimer